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Studies have shown that sleep recovery following diﬀerent protocols of forced waking varies according to the level of stress
inherent to each method. Sleep deprivation activates the hypothalamic-pituitary-adrenal axis and increased corticotropin-releasing
hormone (CRH) impairs sleep. The purpose of the present study was to evaluate how manipulations of the CRH system during the
sleep deprivation period interferes with subsequent sleep rebound. Throughout 96 hours of sleep deprivation, separate groups of
rats were treated i.c.v. with vehicle, CRH or with alphahelical CRH9−41, a CRH receptor blocker, twice/day, at 07:00 h and 19:00 h.
Both treatments impaired sleep homeostasis, especially in regards to length of rapid eye movement sleep (REM) and theta/delta
ratio and induced a later decrease in NREM and REM sleep and increased waking bouts. These changes suggest that activation
of the CRH system impact negatively on the homeostatic sleep response to prolonged forced waking. These results indicate that
indeed, activation of the HPA axis—at least at the hypothalamic level—is capable to reduce the sleep rebound induced by sleep
deprivation.
1. Introduction
One of the most interesting sleep phenomena is its homeo-
static regulation, which can be manifest by the rebound in
sleep that ensues after total or partial sleep deprivation, for
example, increased time spent in sleep during the recovery
period [1]. This phenomenon, known as sleep rebound, is
also observed after deprivation of selected sleep stages, when
recovery of the suppressed stage is observed [2]. However,
sleep deprivation is considered a form of stress both in
humans [3] and rats (for review, see [4]), although there is
not complete agreement on the matter [5]. Animal models
of sleep deprivation indicate that not only the loss of sleep
per se, but also the method employed to induce sleep depri-
vation generates stress, resulting in increased activity of the
hypothalamic-pituitary-adrenal (HPA) axis, with elevated
corticosterone (CORT) and adrenocorticotropic (ACTH)
plasma levels and adrenal hypertrophy [6–9]. Additional
data demonstrate that sleep deprivation induces increased
immunoreactivity [10] and expression of hypothalamic CRH
[11].
Interestingly stressors can induce specific changes in
sleep patterns, including increased REM sleep after immo-
bilization stress [12], increased slow wave sleep after social
defeat stress [13], and decreased REM sleep after foot-
shock [14–16]. When associated with sleep deprivation,
however, immobilization stress inhibits the homeostatic
REM sleep rebound [17], whereas intermittent chronic
foostshock exacerbates the expression of REM sleep during
recovery, in an apparently prolactin- and CORT-dependent
eﬀect [18]. Curiously, both exogenous corticosterone admin-
istration and dexamethasone treatment inhibit sleep in
unstressed rats [19, 20] or after immobilization stress
[21], indicating that other mediators participate in this
phenomenon. Corticotropin-releasing hormone (CRH), the
primary orchestrator of the endocrine stress response, is
synthesized in the paraventricular nucleus of the hypotha-
lamus [22] and is a major regulator of waking in rats [23–
25]. It increases neuronal excitability and convulsions [26],
and stimulates the locus coeruleus noradrenergic neurons
[27]. CRH receptors are densely distributed in basal pros-
encephalic areas, thalamus, hypothalamus, mesencephalus,
2 International Journal of Endocrinology
brainstem, and pons [28], areas which are involved in
cerebral activation and waking maintenance [29].
The pioneering study by Ehlers and coworkers [25]
on the eﬀects of CRH on sleep in rats demonstrates that
low doses of this peptide reduce slow wave sleep (NREM)
and low frequency activity. However, in high doses, CRH
exhibits an opposite eﬀect and reduces fast frequency
activity (32–64 Hz). In human beings, however, peripheral
administration of CRH does not significantly alter REM sleep
[30]. Moreover, CRH modulates the homeostatic rebound
induced by sleep deprivation, by increasing REM sleep
rebound when administered immediately after the sleep
deprivation procedure [31]. In contrast, α-helical-CRH9−41
(αhCRH), a CRH receptor blocker, prevents immobilization
stress-induced sleep rebound and does not influence sleep in
stress-free conditions [32].
In an attempt to determine the role of hormones of the
HPA axis, we recently demonstrated that 96 hours of REM
sleep deprivation together with repeated administrations of
metyrapone, a corticosterone synthesis inhibitor, impaired
sleep deprivation-induced NREM compensation [33]. We
then hypothesized that increased production of CRH elicited
by removal of the CORT negative feedback signal at the
hypothalamic level [34] could be, at least in part, respon-
sible for this eﬀect. If this hypothesis were correct, then
i.c.v. administration of CRH in sleep-deprived rats should
produce similar results to those obtained with metyrapone,
and α-helical-CRH9−41 and should increase sleep rebound in
these animals.
2. Methods
2.1. Subjects. Male adult Wistar rats (350–450 g) from
the animal facility of the Department of Psychobiology—
UNIFESP—were used (eight to ten animals per group)
and prior approval from the Ethics Research Committee
of Universidade Federal de Sa˜o Paulo was obtained in
accordance with international guidelines for care in animal
research (CEP 0125/04). Constant 12 hours light-dark cycle
(fluorescent white lamps-lights on at 7:00 h) and 20–22◦C
temperature were maintained in all experimental rooms
throughout the experimental protocol. Rats were allowed
free access to food and water.
2.2. Electrophysiological Procedures. Under ketamine-xyla-
zine anaesthesia (9.0–10.5 mg/kg, i.p.), rats were fitted with
electrodes to monitor the sleep-wake cycle: two bipolar elec-
trodes placed ipsilaterally with stainless-steel micro-screws
(0.9 mm in diameter) were used for EEG monitoring: one
pair on the right lateral parietoparietal (for minimum theta
activity EEG) and the other on the left medial frontoparietal
(for maximum theta activity EEG) areas [35, 36]. One pair of
insulated nickel-chromium flexible fine wire electrodes was
implanted in the dorsal neck muscle for EMG recording.
For intracerebroventricular—i.c.v. injections, a 22-gauge
stainless steel guide cannula (constructed from hypodermic
needle, Becton Dickinson, Brazil, cut at 10 mm in length)
was inserted 1.0 mm posterior to bregma, 1.4 mm lateral
to midline, and 3.4 mm ventral to dura membrane, within
the EEG electrodes. The guide cannula was covered with
an easily removable lid adopted from a fine stainless steel
wire, which was inserted tightly onto the guide cannula hole.
After the surgical procedure, antibiotics (Pentabio´tico Fort-
Dodge, Brazil) and sodium diclofenac were administered
and the animal was allowed to recover from surgery for 15
days. Three days before the beginning of experiments, lateral
ventricular cannula placement was verified by assessing the
drinking response elicited to up to 5 nmol angiotensin II
administration. After the multiple injections schedules, the
ventricular cannula placement was confirmed postmortem
by injection 3 μL of methylene blue followed by microscope
visualization. Animals were habituated to the cables and
to the recording environment for 3 days before baseline
recording. Baseline sleep was recorded on two consecutive
days (2 × 24 hours) and the parameters are represented by
the average of these two days. After the baseline recording, in
the period that preceded REM sleep deprivation (REMSD),
animals were adapted to the sleep deprivation chambers for
30 minutes per day for three consecutive days.
Electrophysiological signals were recorded on a digital
polygraph (Neurofax QP 223 A Nihon Kohden Co., Tokyo,
Japan). After conventional amplification, the EEG signals
were conditioned through analog filters, using cut oﬀ
frequencies of 1.0 Hz and 35.0 Hz and were then sampled
at 200 Hz using a 16 bit A/D converter. Recordings were
displayed on 10 s epochs and submitted oﬀ-line to visual
scoring routine, as described previously [37]. In summary
the stages of wake-sleep were defined as follows: (a) waking
(low voltage and high frequency EEG, whereas EMG displays
high voltage during active waking or low during voltage
quiet waking); (b) NREM sleep (EEG high voltage within
slow waves and spindles, also classified, separately, in low—
between 2.0 and 3.0 μV, and high amplitudes—from 3.0 μV
on, and low EMG amplitude); and (3) REM sleep (low EEG
voltage with prominent theta rhythm on medial EEG devi-
ation accompanied of the very low EMG activity). Each 10 s
epoch was characterized by the predominant wave pattern
present in more than half of the epoch. In some periods,
interference or noise made it impossible to characterize the
behavioral state and a critical evaluation of the previous and
subsequent periods was made. The percentage of 10 s periods
excluded from sleep scoring was below 9%.
The parameters used for sleep analysis were the follow-
ing: total sleep time, total NREM time (considering low
and high amplitude fractions) REM time and bouts, and
total wake time—active and quiet periods—and episodes
of waking (2.0 minutes). Fast Fourier Transform (Hanning
window) was computed on 256 points for each 10 s epochs
(corresponding to each vigilance state) with a resolution of
0.78 Hz (null value was attributed to the remaining time).
Nonoverlapping bands were set giving 0.5 Hz bins from
1.0 to 5.0 Hz, and 1.0 Hz bins from 5.1 Hz to 25.0 Hz;
those above 25.0 Hz were discarded from the analysis. EEG
epochs containing noise or artifacts (those that did not
allow doubtful behavioral state classification) were excluded
from the analysis by visual inspection and/or spectral tools
(e.g., if average power exceeded 2000 μV2 over a 1.0–25.0 Hz
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frequency range). Slow wave activity was calculated as mean
power density on 1.0–4.0 Hz band (delta) and the theta-delta
ratio, dividing the power density of the fast theta (6.0–9.0 Hz)
band by the mean power density on the delta band. Although
two ipsilateral bipolar electrodes were used for sleep scoring,
only the lateral parietoparietal deviation was used for
spectral data analysis, except for the theta-delta ratio, when
the two deviations were employed (the lateral to delta and
the medial frontoparietal to theta activity measures).
2.3. REM Sleep Deprivation (REMSD) Procedure and Drug
Administration. Sleep deprivation was accomplished by the
single platform method, in which each animal was placed
onto a narrow cylindrical platform, 6.5 cm in diameter, sur-
rounded by water to about 1 cm below the platform surface.
This method is well known to selectively suppress REM sleep;
however, it also produces partial NREM deprivation, with
37–50% reduction from baseline levels [38, 39].
CRH (Sigma, USA): 3 μg/animal [22, 40, 41] or αhCRH
(Sigma, USA): 20 μg/animal [42–44] were diluted in artificial
cerebrospinal fluid—ACSF (NaCl 127 mM, KCl 2.5 mM,
MgCl2 0.9 mM, Na2HPO4 1.2 mM, CaCl2 1.3 mM, NaHCO3
21 mM, C6H12O6 3.4 mM, and pH 7.3, sterile- and pyrogen-
free) and administered twice/day, at 7:00 h and 19:00 h, in
addition to a single injection at the end of the REM depriva-
tion period, making a total of nine administrations. Control
animals were treated with ACSF under the same scheme.
Final volume of each i.c.v. injection was 3-4 μL, delivered at a
flow rate of 1.5 μL/minute with an injection cannula, made
from another 30-gauge dentist needle (Becton Dickinson,
Brazil, cut at 25 mm in length, but inserted into guide
cannula up to 10.5 mm limit) connected to a polypropylene
tubing (PE 10, Becton Dickinson, USA) which, in turn, was
linked on another terminal end to a 10 μL microsyringe
(Hamilton, USA), placed onto a automatic microinfusion
pump (Insight, Brazil). Prophylactic aseptic techniques were
strictly employed during all administrations and less than
20% of animals were not used during the chronic experi-
ments because of signs of infection (e.g., fever, weight loss,
apathy, wet fur, and poor physical appearance). After four
days under this protocol, rats were returned to sleep freely
in their individual home cages (recovery period). Over the
subsequent three days, the rats were continuously monitored.
2.4. Plasma Hormone Determination. Trunk blood was
obtained by decapitation, approximately 2 hours after the last
administration from matched groups, run simultaneously
with the sleep study. During this period, the REMSD
animals were not allowed to sleep (they were put back into
the deprivation chambers). Blood was collected in chilled
K2EDTA (0.46 mM, e.g., 7.5% solution at a volume of 0.1 mL
diluted in 5 mL of blood)-containing vials, centrifuged at
2300 rpm at 4◦C for 20 minutes, and plasma was collected
and frozen at −20◦C for further analysis. Plasma ACTH
was determined by sequential immunometric assay (DPC
Immulite, Los Angeles, CA) and the sensitivity of the method
is 9 pg/mL, and intra- and interassay variations are 9.4%
and 9.6%, respectively. Corticosterone levels were assayed by
specific radioimmunoassay (INC Biomedicals, Costa Mesa,
CA). The sensitivity of the assay is 1.25 ng/mL and the intra-
and inter-assay variations are, respectively 6.5% and 7.1%, as
informed by the manufacturer. All samples were assayed in
duplicate.
2.5. Statistics. Hormonal data were analyzed by a two-way
ANOVA, with main factor Group (CTL—control home
cage and REM sleep deprivation—REMSD) and Treatment
(ACSF, CRH, and αhCRH). Sleep parameters were analyzed
by a two-way ANOVA for repeated measures, with main
factors Treatment (ACSF, CRH, and αhCRH) and Day
(repeated measure: Baseline and Recovery days 1 [R1], 2
[R2], and 3 [R3]). The spectra power density was analyzed
by Student’s t tests for independent samples, every 12 hours
period, for each behavioral state separately. The theta-delta
ratio was analyzed by covariance analyses (ANCOVA) where
the baseline index was the predictive factor and treatments,
the independent variable. All EEG data were analyzed
during the light and dark phases, separately. Posthoc analysis
was performed by the Newman-Keuls test. The level of
significance was set at P ≤ .05.
3. Results
3.1. HPA Axis Hormones (Figure 1)
ACTH. There was a significant interaction between Group
and Treatment (F2,54 = 0.67, P ≤ .0005), in which
REMSD + ACSF animals showed higher ACTH levels than
their CTL counterparts (P ≤ .05), whereas REMSD+ αhCRH
animals exhibited lower levels than CTL+ αhCRH ones (P ≤
.05). In addition, in CTL animals, both CRH and αhCRH
resulted in higher ACTH levels than ACSF administration
(P ≤ .0005).
Corticosterone. Again, a significant interaction between
Group and Treatment (F2,53 = 19.52, P ≤ .00005) was
found. Newman-Keuls analysis of this interaction showed
that all groups exhibited higher corticosterone plasma levels
than CTL + ACSF animals (CTL+CRH: 853.3%, P ≤
.0005; CTL + αhCRH: 230.5%, P ≤ .05; REMSD + ACSF:
115.4%, P ≤ .05; REMSD + CRH: 575.6%, P ≤ .0005 and
REMSD + αhCRH: 747.6%, P ≤ .0005). However, CRH
treatment in REMSD rats resulted in lower CORT levels
than in CTL rats (−29.1%, P ≤ .01), although they were
still higher than REMSD+ACSF animals (213.6%, P ≤
.0005). On the other hand, αhCRH treatment led to higher
CORT levels in REMSD than in CTL (156.4%, P ≤ .0005)
and REMSD + ACSF rats (293.5%, P ≤ .0005). Finally,
CORT concentrations were lower in CTL + αhCRH than in
CTL+CRH (−65.33%, P ≤ .0005).
3.2. Sleep Parameters
3.2.1. Total Sleep Time (Figure 2)
Light Phase. A main eﬀect of Day (F3,63 = 2.52, P ≤ .00001)
was found. Reduced sleep time was observed on the 2nd
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(10.2%, P ≤ .05) and 3rd recovery days when compared to
baseline (22.9%, P ≤ .0005).
Dark Phase. Again main eﬀect of Day was observed (F3,63 =
13.89, P ≤ .00001). Animals showed 24.4% increased sleep
time on the first recovery day (P ≤ .001).
3.2.2. Total NREM Time (Figure 2)
Light Phase. A main eﬀect of Day was detected (F3,63 = 6.84,
P ≤ .0005). Total NREM was reduced (20.3%) on the 3rd
recovery day, relative to baseline.
Dark Phase. An eﬀect of Day emerged (F3,63 = 9.05, P ≤
.00005) and the rats showed more NREM (16.8%, P ≤ .01)
than baseline.
3.2.3. REM Sleep Time (Figure 3)
Light Phase. A main eﬀect of Day was found (F3,63 = 22.70,
P ≤ .00001). Animals showed an increase on this phase
(53.3%, P ≤ .0005) during the first recovery day, whereas a
reduction of REM was also observed during the last recovery
day (32.8%, P ≤ .02).
Dark Phase. Again, a main eﬀect of Day was found (F3,63 =
15.32, P ≤ .00001) and the animals showed an increase of
71.2% (P ≤ .0005) during first recovery day, when compared
to baseline amounts.
3.2.4. REM Bouts (Figure 3)
Light Phase. A main eﬀect of Day was found (F3,63 = 11.29,
P ≤ .00001) and a decrease of REM bouts was detected on
the 3rd recovery day (39.3%, P ≤ .0005).
Dark Phase. Again, a main eﬀect of Day was detected (F3,63 =
7.83, P ≤ .0005). During the first recovery day, animals
displayed more bouts than baseline sleep (P ≤ .01).
3.2.5. Mean Length of REM Episodes (Figure 3)
Light Phase. A two-way interaction between Day and Treat-
ment was found (F6,63 = 3.59, P ≤ .005). Posthoc
analysis showed that REM episodes were longer after ACSF
administration than at baseline (124.2%, P ≤ .0005).
Administration of CRH (45.5%, P ≤ .005) and αhCRH
(40.0%, P ≤ .005) shortened the length of REM episodes
during the first recovery day compared to ACSF-treated rats.
Dark Phase. There was a Day eﬀect (F3,57 = 4.10, P ≤ .02), in
which the animals showed longer REM episodes on the first
recovery night (28.7%, P ≤ .05).
3.2.6. Total Wake Time (Figure 4)
Light Phase. A two-way interaction between Day and Treat-
ment was detected (F6,63 = 3.53, P ≤ .005) and post-hoc
tests revealed that CRH-treated animals spent more time
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Figure 1: ACTH and CORT Plasma Levels. CTL, Control; ACSF,
artificial cerebrospinal fluid; CRH, corticotrophin-releasing hor-
mone; αhCRH, alpha-helical CRH9−41∗- diﬀerent from CTL+ACSF,
#- diﬀerent from PSD+ACSF, and †- diﬀerent from CTL+CRH, ‡-
diﬀerent from CTL+αhCRH; ANOVA, followed by Newman-Keuls
test, P ≤ .05.
awake during the last recovery day than in baseline (41.8%,
P ≤ .01).
Dark Phase. A two-way interaction was found between Day
and Treatment (F6,63 = 2.94, P ≤ .02) and both CRH- and
αhCRH-treated rats showed less total wake during the first
recovery day than on baseline (19.1%, P ≤ .05 and 21.4%,
P ≤ .05, resp.).
3.2.7. Number of Awakenings (Figure 4)
Light Phase. A two-way interaction was found (F6,63 = 2.61,
P ≤ .05). Post-hoc tests showed that CRH-treated rats
displayed more events of awakenings during the last recovery
day relative to baseline (62.6%, P ≤ .05).
Dark Phase. No changes were found.
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Figure 2: NREM Sleep. Data were obtained in recording periods of approximately 11 hours during the light and dark phases. ACSF, artificial
cerebrospinal fluid; CRH, corticotrophin-releasing hormone; αhCRH, alpha helical CRH9−41; REMSD, 96 hours REM sleep deprivation
period; Rec. Recovery period. The white back panels indicate the light phase and the shaded ones, the dark phase. ∗- diﬀerent from baseline,
eﬀects of day are indicated by connecting lines above the symbols. ANOVA, followed by Newman-Keuls, P ≤ .05.
3.3. Spectral Data
3.3.1. Spectral Power during NREM (Figure 5)
Light Phase. During the third recovery day, CRH-treated
animals showed reductions in the 19.01–20.0 Hz (19.2%,
P ≤ .05) and 20.1–21.0 Hz bands (18.4%, P ≤ .05)
when compared to ACSF-treated rats. Moreover, increased
power above ACSF animals was observed in the 1.6–
2.0 Hz band (53.3%, P ≤ .02) in CRH- and in the
1.0–1.5 Hz band (34.8%, P ≤ .05) in αhCRH-treated
groups.
Dark Phase. On the second recovery day, αhCRH led to
increased power in the 1.0–3.0 Hz bands (average of 4 bins
of 0.5 Hz each = 53.7%, P ≤ .05), when compared to ACSF
group and increased all bands above 6.0 Hz when compared
to CRH-treated rats (average of 19 bins of 1.0 Hz each =
28.5%, P ≤ .05). Finally, during the last recovery day,
αhCRH produced an increase in all bands above 7.0 Hz when
compared to CRH-treated animals (average of 18 bins of
1.0 Hz each = 27.1%, P ≤ .05).
3.3.2. Theta-Delta Ratio (Figure 6)
Light Phase. A main eﬀect of Treatment was detected for
active wake (AW) (F2,20 = 4.45, P ≤ .05) and post-hoc
analysis showed that CRH animals showed reductions of
θ/δ relative to ACSF (12.3%, P ≤ .05) and αhCHR rats
(17.6%, P ≤ .01). During Quiet Wake (QW), eﬀect of
Treatment was again revealed (F2,19 = 3.94, P ≤ .05),
and CRH-displayed smaller θ/δ ratio than αhCHR-treated
animals (16.8%, P ≤ .01). No eﬀects were found in Low-
Amplitude NREM (L-NREM) or in High-Amplitude NREM
(H-NREM) during the recovery period. During REM sleep,
a significant eﬀect of Treatment (F2,20 = 7.14, P ≤ .005)
and an interaction between Day and Treatment (F4,40 =
2.90, P ≤ .05) were found. In regards to the Treatment
factor, CRH-treated animals showed a smaller θ/δ ratio
than ACSF- (15.6%, P ≤ .01) and αhCHR-treated animals
(22.1%, P ≤ .005). No post-hoc diﬀerences were detected for
the interaction.
Dark Phase. During AW a main eﬀect of Day was observed
(F2,40 = 12.61, P ≤ .00005); however, the post-hoc analysis
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Figure 3: REM Sleep. Data were obtained in recording periods of approximately 11 hours during the light and dark phases. ACSF, artificial
cerebrospinal fluid; CRH, corticotrophin-releasing hormone; αhCRH, alpha helical CRH9−41; REMSD, 96 hours REM sleep deprivation
period; Rec. Recovery period. The white back panels indicate the light phase and the shaded ones, the dark phase. ∗- diﬀerent from baseline,
‡- diﬀerent from ACSF group. Main eﬀects of day are indicated by connecting lines above the symbols. ANOVA, followed by Newman-Keuls,
P ≤ .05.
did not revealed any diﬀerences among the days. For QW,
main eﬀects of Treatment (F2,20 = 3.59, P ≤ .05) and Day
(F2,40 = 10.27, P ≤ .0005) were found. The Newman-Keuls
test showed that CRH treatment reduced θ/δ ratio when
compared to ACSF (9.7%, P ≤ .05) and αhCHR (15.0%,
P ≤ .005) treatments. In regards to the eﬀect of Day, there
was a reduction of θ/δ on the 3rd compared to the 1st
recovery day (6.1%, P ≤ .05). No eﬀects were detected in
L-NREM, whereas a main eﬀect of Day was detected in H-
NREM (F2.40 = 3.35, P ≤ .05) and the post-hoc analysis
showed that the θ/δ ratio was reduced on the 2nd and 3rd
recovery days (9.7%, P ≤ .0001 and 13.7%, P ≤ .0001, resp.).
During REM sleep, a main eﬀect of Treatment was detected
(F2,18 = 4.00, P ≤ .05) and CRH treatment reduced the θ/δ
ratio compared to ACSF (12.4%, P ≤ .05) and to αhCHR
(17.1%, P ≤ .01).
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Figure 4: Awake. Data were obtained in recording periods of approximately 11 hours during the light and dark phases. ACSF, artificial
cerebrospinal fluid; CRH, corticotrophin-releasing hormone; αhCRH, alpha helical CRH9−41; REMSD, 96 hours REM sleep deprivation
period; Rec, Recovery period. The white back panels indicate the light phase and the shaded ones, the dark phase. ∗- diﬀerent from baseline.
Main eﬀects of day are indicating by connecting lines above the symbols. ANOVA/Newman-Keuls, P ≤ .05.
4. Discussion
The main results of the present study can be summarized
as follows: (1) both CRH and αhCRH increased ACTH and
CORT secretions, although these were lower in REMSD than
in control rats; (2) both peptides impaired sleep in later
periods of the recovery sleep, but did not interfere with
the immediate sleep rebound, except for a reduction in the
length of REM sleep episodes; (3) rats treated with αhCRH
exhibited more high frequency bands in NREM than rats
treated with CRH during the last dark phase of the recovery
period; and (4) CRH-treated rats exhibited lower theta/delta
ratio, indicating an impairment of the homeostatic sleep
rebound.
As expected, REMSD resulted in increased secretion of
ACTH and CORT levels, relative to control, nondeprived
rats. Repeated administration of CRH, during REMSD,
however, led to opposite eﬀects, for example, levels in
REMSD were lower than those of control rats. This result
can be explained by the well-known stimulating eﬀect
that REMSD exerts on the CRH-producing neurons, with
increased mRNA [11] and immunoreactivity of CRH [10]
in the PVN, which could lead to lower density of CRH
receptors. In fact, a previous study showed that REMSD
results in lower CRH receptor density in the pituitary and
striatum [45]. Despite that, no major eﬀects in the sleep
macrostructure were observed during rebound, except for a
reduction of the length of REMS episodes.
We found that αhCRH reduced ACTH, but increased
CORT release by almost 3-fold in REMSD rats compared
to CSF-treated animals. Alpha-helical CRH-induced
attenuation of the ACTH response to REMSD resembled
those of a previous study with restraint stress [46]. Some
studies indicate that in order to achieve an eﬀective
blockade of the behavioral stress response, αhCRH dose
must be higher than 25 μg (in the present study the dose
was 20 μg/animal) [42, 47, 48], even though ACTH and
CORT secretions may still not be completely suppressed
[42]. Some studies even indicate that αhCRH, in doses
higher than 25 μg, acts as an agonist of the type 1 CRH
receptor (CRH-R1), leading to behavioral and hormonal
responses similar to those elicited by CRH [49–52].
αhCRH antagonist action is evident in stressful, but not
under basal conditions [53–55], possibly due to the fact
that it binds more eﬃciently to CRH-R2 receptors [56],
whereas CRH-R1 is the predominant type in the pituitary
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Figure 5: Spectral Power During Total NREM on the 2nd (a) and
3rd (b) Recovery Dark Phases. Results are expressed as percentage of
ACSF-treated group, obtained from the mean power of each spectra
band. ACSF, artificial cerebrospinal fluid; CRH, corticotrophin-
releasing hormone; αhCRH, alpha helical CRH9−41. Grey line above
graphics indicates diﬀerences of αhCRH from ACSF and black ones,
the diﬀerence between the CRH and αhCRH treatments. Student’s
t tests, P ≤ .05.
[57–59]. Interestingly, the distribution of CRH receptors
in sleep-related areas indicates that CRH-R1 is densely
located in the laterodorsal tegmental nucleus and CRH-
R2, in the dorsal raphe, without any overlapping [59],
suggesting that both receptors types may be involved in sleep
regulation.
Increased NREMS is seen with higher doses of αhCRH
(i.c.v., 25 μg/rat) within two hours of drug administration
[43], whereas a higher dose (i.c.v., 100 μg/rat) prevents
immobilization stress- and sleep deprivation-induced sleep
rebound [32, 60]. It is possible that the dose of αhCRH
used in the present study, also infused i.c.v., was not high
enough to produce the same sleep changes as reported by
Gonzalez and Valatx’s [60] paper, however, in their study, the
compound was administered every two hours throughout
the deprivation period, mounting to a much larger dose in
a much shorter period of sleep deprivation. Moreover, this
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Figure 6: Theta/Delta. Theta/delta ratio is shown as mean of
the total power in fast the θ (6.6–9.0 Hz) band divided by total
power in fast δ (2.5–4.0 Hz) band, computed throughout ∼11
hours period in the light and dark phases of the recovery period.
ACSF, artificial cerebrospinal fluid; CRH, corticotrophin-releasing
hormone; αhCRH, alpha helical CRH9−41; AW, active wake; QW,
quiet wake; L NREM, low amplitude NREM sleep; H NREM, high
amplitude NREM sleep; PS, REM sleep; Rec. Recovery period. The
white panels indicate the light phase and the gray ones, the dark
phase. ∗- diﬀerent from baseline, #- diﬀerent from ACSF group, and
‡- diﬀerent from αhCRH group. Main eﬀects of sleep parameter are
indicated by connecting lines above the bars. ANCOVA, followed by
the Newman-Keuls test, P ≤ .05.
schedule of administration is likely to maintain receptors
blocked throughout the entire sleep deprivation period.
The most remarkable eﬀect of CRH and αhCRH treat-
ments in sleep macrostructurewas a shortening of the length
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of REMS episodes, compared with vehicle-infused rats,
during the first light period of recovery sleep, indicating
and impairment of REM sleep regulation. The influence
of CRH on REM sleep appears to be bimodal. On the
one hand, intra-hippocampal CRH infusion reduces theta
rhythm by acting on both CRH receptors, present in
hippocampal CA1 field and dentate gyrus [61]. On the other
hand, overexpression of CRH leads to more spontaneous
and sleep deprivation-induced REM sleep [62]. At present,
it is not possible to determine how both drugs, acting
predominantly through diﬀerent CRH receptors, could lead
to similar results in REM sleep regulation. One possibility
may involve changes in serotonergic transmission, since it
has been shown that the raphe nucleus projects heavily
to the hippocampus and medial septum [63, 64] and that
stimulation of this region suppresses theta rhythm in the
EEG, regardless of the activity in the septal area [65, 66].
Lesions of the raphe may result in permanent hippocampal
theta rhythm [67] and infusion of 5-HT1A agonist in
the dorsomedial raphe impairs hippocampal and cortical
theta rhythm [68]. Considering that the predominant CRH
receptor in the raphe is the low aﬃnity CRH-R2 [61] and that
activation of these receptors with high or repeated αhCRH
administrations lead to serotonin release in this area [69],
there is a possibility that the treatment used in the present
study might have caused an increase in serotonergic activity,
which impaired theta rhythm and, consequently, REM
sleep.
Regarding sleep microstructure, during NREM sleep,
αhCRH produced an increase in the high frequency bands
during the last two dark phases, compared to CRH, sug-
gesting opposite homeostatic and late circadian responses
exerted by these peptides. Thus, αhCRH-treated rats
appeared to exhibit shallower NREM sleep than CRH-treated
rats, considering that high frequency bands are predominant
during waking. However, shallower NREM sleep during the
active period of rats indicates normal circadian rhythm and,
therefore, a return to homeostasis. CRH also reduces low
frequency (1.0–6.0 Hz) spectral potency in rats [25] and in
humans, there is an increase in waking and delta sleep EEG
sigma band (11.0–15.0 Hz) [70]. CRH receptors are present
in several thalamic nuclei [71, 72], although they inhibits
spontaneous activity of these neurons [73]. Activation of
these receptors might result in inactivity of reticular cells,
responsible for the generation of synchronization of low
frequency waves in the cortical EEG [74] and reduction of the
low frequency power spectrum [25]. CRH deleterious eﬀects
on sleep appear to be mediated by CRH-R1, since R129919,
a specific CRH-R1 antagonist increases slow wave sleep in
depressed patients [75]. This may explain why αhCRH did
not aﬀect low frequency power spectrum, since this sub-
stance blocks preferentially the type 2 CRH receptor. More-
over, CRH mRNA expression on the posterior nucleus of the
thalamus is augmented during the rat resting period [76, 77].
Activation of this nucleus is related to the generation of high
frequency β waves and suppression of δ and spindle activity
during slow wave sleep [78, 79]. Collectively, these data
could explain the increased potency of EEG high frequency
bands.
A relatively recent index is the theta/delta (θ/δ) ratio,
which represents a marker of homeostatic sleep compensa-
tion and is known to be increased after sleep deprivation [80,
81], being characteristic of each sleep phase [82]. In humans,
for instance, this increase takes place during the dark period,
which corresponds to the resting period [83]. The reduction
of θ/δ ratio in CRH-treated rats during waking and REM
sleep suggests that the homeostatic compensation is flawed,
because during REM sleep decreased delta and/or increased
theta activity is supposed to occur.
Theta rhythm is one of the most prominent features
of REM sleep in the rat [35, 84], which is generated
by cell populations that flow to CA1 stratum oriens and
dentage gyrus stratum molecular [85, 86]. The reduction of
theta/delta rhythm in CRH-treated rats might have occurred
due to a reduction of theta potency, rather than an increase
in delta power. The reason for this conclusion is threefold:
(1) the reduction of the index took place during waking
and REM sleep, when theta predominates; (2) there were
no changes during low and high NREM sleep, when delta
predominates; and (3) as a general rule, low frequencies (1.0–
5.0 Hz) were unchanged during NREM sleep.
In conclusion, chronic CRH administration during REM
sleep deprivation impaired the homeostatic compensation
phenomenon, likely due to its excitatory action on neuronal
tissue. This impairment occurred in the sleep macrostruc-
ture, with shortening of REM sleep episodes, as well as in
the microstructure, in later phases of the recovery period.
Because αhCRH acts at the CRH-R2 and may have agonistic
properties when repeatedly administered in high doses, it
produced paradoxical changes on hormone secretion and
sleep homeostasis, being, sometimes, similar to CRH.
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